Fresh frozen plasma (FFP) is available in units of approximately 200 mL. FFP contains normal levels of all coagulation factors (about 1 unit/mL of each factor). FFP is used to correct coagulation factor deficiencies and to treat thrombotic thrombocytopenia purpura or other thrombotic microangiopathies. FFP is also used to correct or prevent coagulopathy in trauma patients receiving massive transfusion of packed red blood cell (PRBC). An FFP:PRBC ratio of 1:2 or more is associated with improved survival in trauma patients receiving massive transfusions, regardless of the presence of a coagulopathy.
Cryoprecipitate is made from fresh plasma by cooling the plasma to 4°C and collecting the precipitate. One unit of cryoprecipitate has a volume of approximately 15–20 mL and contains approximately 250 mg of fibrinogen and between 80 and 100 units of factor VIII and von Willebrand factor. Cryoprecipitate is most commonly used to supplement fibrinogen in cases of acquired hypofibrinogenemia (eg, acute DIC) or in rare instances of congenital hypofibrinogenemia. One unit of cryoprecipitate will raise the fibrinogen level by about 8 mg/dL (0.24 mcmol/L). Cryoprecipitate is sometimes used to temporarily correct the acquired qualitative platelet dysfunction associated with kidney disease.
et al. Plasma transfusion demystified: a review of the key factors influencing the response to plasma transfusion. Lab Med. 2017 May 1;48(2):108–12.
et al. Blood transfusion therapy. Med Clin North Am. 2017 Mar;101(2):431–47.
et al. Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis. Br J Haematol. 2017 Jul;178(1):137–51.
MM; ICC PBM Frankfurt 2018 Group. Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA. 2019 Mar 12;321(10):983–97.
N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):585–94.